PDL BioPharma (PDLI) Misses Q3 EPS by 19c

PDL BioPharma (NASDAQ: PDLI) reported Q3 EPS of $0.42, $0.19 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $124.6 million versus the consensus estimate of $164.8 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Hitachi Ltd. (HIT) Misses Q2 EPS by 7c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c